SavedAdd your journal

Journals / Turkish Journal of Health Science and Life / 2019 / Cilt: 2 - Sayı: 2

DEMOGRAPHIC AND CLINICAL FEATURES OF PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME IN ANTALYA

Mesut GÖÇER
Pages
1–7
Publication Date
2019-12-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Hydroxychloroquine is the most preferred drug as a therapeutic agent Conclusions: Features of primary SS obtained in this study are similar to those found in some national and international studies, but we observed lung involvement higher male than female.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AbstractBackground: Sjögren’s syndrome (SS) is an autoimmune disease with a broad range of systemic manifestations.
📊
Key Findings & Data:Methods: In this study were included the patients with primary SS (pSS) diagnosed between 2004-2014 years at the Akdeniz University Hospital, Antalya, Turkey.
💡
Conclusion & Impact:Hydroxychloroquine is the most preferred drug as a therapeutic agent Conclusions: Features of primary SS obtained in this study are similar to those found in some national and international studies, but we observed lung involvement higher male than female.
🔬Design:Research Article
📍Scope:2004-2014 Verileri
⚙️Variables:Sjögren Syndrome · Demographic · Clinical Features

Abstract

AbstractBackground: Sjögren’s syndrome (SS) is an autoimmune disease with a broad range of systemic manifestations. This study was conducted to determine demographic and clinical features of primary SS patients. Methods: In this study were included the patients with primary SS (pSS) diagnosed between 2004-2014 years at the Akdeniz University Hospital, Antalya, Turkey. The clinical and laboratory features were retrospectively obtained from medical charts. Results: We had 718 patients with suspected pSS at 10 years. 372 patients were classified as pSS according to 2012 American Collage of Rheumatology Classification Criteria for Sjögren’s Syndrome. pSS was more frequent among women and ratio women/men was 11/1. The mean age at the time of pSS diagnosis was 50.3±11.81 years. In men, pSS was diagnosed at an older age, and lung involvement was common than women. Joint involvement is the most common extraglandular involvement. Anemia is present in 21.1 % of the patients. Malignancy was diagnosed in 14 patients (3.8%) and 18 patients died (4.8%) during follow-up. Hydroxychloroquine is the most preferred drug as a therapeutic agent Conclusions: Features of primary SS obtained in this study are similar to those found in some national and international studies, but we observed lung involvement higher male than female.

🔖

Cite This Article

GÖÇER, M. (2019). DEMOGRAPHIC AND CLINICAL FEATURES OF PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME IN ANTALYA. Turkish Journal of Health Science and Life, Cilt: 2 - Sayı: 2, 1–7. https://ajindex.com/articles/808933

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. References 1) Fox RI (2005) Sjogren's syndrome. Lancet 366(9482):321-31.2) Kassan SS, Moutsopoulos HM (2004) Clinical Manifestations and Early Diagnosis of Sjögren Syndrome. Arch Intern Med 164:1275-1284.3) Moutsopoulos HM (2014) Sjögren's syndrome: a forty-year scientific journey. J Autoimmun 51:1-9. doi: 10.1016/j.jaut.2014.01.0014) Palm Q, Garen T, Enger TB, Jensen JL, Lund MB, Aalokken TM, Gran JT (2013) Clinical pulmonary involvement in primary Sjogren’s syndrome: prevalence, quality of life and mortality-a retrospective study based on registry data. Rheumatology (Oxford) 52(1):173-9. doi: 10.1093/rheumatology/kes3115) Voulgarelis M, Tzioufas AG, Moutsopoulos HM (2008) Mortality in Sjögren's syndrome. Clin Exp Rheumatol 26(5 Suppl 51):S66-71. 6) Weng MY, Huang YT, Liu MF, Lu TH (2011) Incidence and mortality of treated primary Sjogren's syndrome in Taiwan: a population-based study. J Rheumatol 38(4):706-8. 7) Kruize AA, Hené RJ, van der Heide A, Bodeutsch C, de Wilde PC, van Bijsterveld OP, de Jong J, Feltkamp TE, Kater L, Bijlsma JW (1996) Long-term followup of patients Arthritis Rheum 39:297–303. 8) Davidson BK, Kelly CA, Griffiths ID (1999) Primary Sjögren’s syndrome in the North East of England: a long-term follow-up study. Rheumatology (Oxford) 38:245–3. 9) Martens PB, Pillemer SR, Jacobsson LT, O'Fallon WM, Matteson EL (1999) Survivorship in a population based cohort of patients with Sjögren’s syndrome, 1976–1992. J Rheumatol 26:1296–300. 10) Pertovaara M, Pukkala E, Laippala P, Miettinen A, Pasternack A (2001) A longitudinal cohort study of Finnish patients with primary Sjögren’s syndrome: clinical, immunological, and epidemiological aspects. Ann Rheum Dis 60:467–72. 11) Ioannidis JP, Vassiliou VA, Moutsopoulos HM (2002) Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren’s syndrome. Arthritis Rheum 46:741–7.12) Alamanos Y, Tsifetaki N, Voulgari PV, Venetsanopoulou AI, Siozos C, Drosos AA (2006) Epidemiology of primary Sjögren’s syndrome in north-west Greece, 1982–2003. Rheumatology (Oxford) 45:187–91.13) Brito-Zerón P, Kostov B, Solans R, Fraile G, Suárez-Cuervo C, Casanovas A, et al (2014) Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. Ann Rheum Dis. doi: 10.1136/annrheumdis-2014-206418.14) Shiboski SC, Shiboski CH, Criswell LA, Baer AN, Challacombe S, Lanfranchi H, et al (2012) Americ